Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy

Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy

Angiogenesis plays a crucial role in tumor development and metastasis. Both bevacizumab and cediranib have demonstrated activity as single anti-angiogenic agents in endometrial cancer, though subsequent studies of bevacizumab combined with chemotherapy failed to improve outcomes compared to chemothe...

Full description

Bibliographic Details
Main Authors: Jianling Bi, Garima Dixit, Yuping Zhang, Eric J. Devor, Haley A. Losh, Andreea M. Newtson, Kristen L. Coleman, Donna A. Santillan, Thorsten Maretzky, Kristina W. Thiel, Kimberly K. Leslie
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Pharmaceuticals
Subjects:
endometrial cancer
bevacizumab
cediranib
patient-derived organoid models
3D culture
personalized medicine
Online Access:https://www.mdpi.com/1424-8247/14/7/682

Similar Items

Similar Items